Format

Send to

Choose Destination
Pharmacotherapy. 2015 Sep;35(9):823-37. doi: 10.1002/phar.1629.

Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.

Author information

1
Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah.
2
VA Salt Lake City Health Care System, Salt Lake City, Utah.
3
Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.

Abstract

There has been a 10-year hiatus in the approval of a new pharmacotherapy for patients with chronic heart failure with a reduced ejection fraction (HFrEF). Combining an angiotensin receptor blocker, valsartan, with sacubitril, an inhibitor of neprilysin, results in increasing levels of natriuretic peptides that counterbalance high circulating levels of neurohormones in HFrEF. This has resulted in the development of a new agent, LCZ696. A comprehensive overview of LCZ696, its pharmacology, its role in the pathophysiology of HFrEF, completed and future clinical trial information, specific critical issues, and the place of LCZ696 in HFrEF therapy are presented.

KEYWORDS:

heart failure with reduced ejection fraction; neprilysin inhibition; pharmacotherapy; systolic heart failure; therapeutic review

PMID:
26406774
DOI:
10.1002/phar.1629
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center